ClearView hit by adverse claims

30 January 2020
| By Oksana Patron |
image
image
expand image

Clearview has announced a significant adverse deterioration in claims and higher than expected lapses for the half-year ended in December, 2019, which are likely to impact its life insurance underlying net profit after tax (NPAT) by -4.7 million and -$1.4 million, respectively, while actual HY20 results are still being finalised.

In the announcement made to the Australian Securities Exchange (ASX), ClearView explained the adverse claims impact, relative to the assumptions adopted in June 2019, by providing a breakdown by product as follows:

  • ClearView LifeSolutions lump sum portfolio -$0.9m (1H FY19: -$0.5m; 2H FY19: +$0.5m)
  • ClearView LifeSolutions IP portfolio -$2.6m (1H FY19: -$1.4m; 2H FY19: -$3.5m)
  • Direct portfolios (closed to new business) -$1.2m (1H FY19: -$0.2m; 2H FY19: -$0.1m)

At the same time, lapses remained elevated with a loss totalling to $1.4m in HY20 against the assumption adopted in June 2019 (1H FY19: -$2.9m,2H FY19: -$2.7m).

According to Clearview, the key contributors to the poor lapse and income protection (IP) claims included, among the others, poor wages growth, rising consumer costs, step premium rating structures, IP product design issue and social trends.

The firm stressed that it remained supportive of the Australian Prudential Regulation Authority’s (APRA) intervention due to the prolonged underperformance of the life insurance sector which included the introduction of IDII Sustainability Measures aimed at imposing a number of measures such as Pillar 2 capital charge across the industry.

“ClearView is a nimble player and is in a strong position to implement any necessary changes relatively quickly. Given APRA’s recent policy measures and the continued underperformance of the IP portfolio, ClearView has already commenced a comprehensive review of its LifeSolutions IP product series with a focus on reviewing product pricing claim rates,” the firm said in the announcement.

“Some insurers appear to be engaging in ‘honeymoon’ discounting to maintain market share rather than focusing on delivering long-term sustainable products and transparent pricing to customers. Clearview is not participating in this approach which is impacting ClearView’s current new business volumes.”

As far as the firm’s wealth management results were concerned, it said the underlying NPAT for the half-year ended in December, 2019 were expected at $1.7 million while funds under management (FUM) would be up 10% to $2.28 billion due to string net inflows of $66 million against of $81 million outflows in 1h FY19).

Read more about:

AUTHOR

Add new comment

The content of this field is kept private and will not be shown publicly.

Recommended for you

sidebar subscription

Never miss the latest developments in Super Review! Anytime, Anywhere!

Grant Banner

From my perspective, 40- 50% of people are likely going to be deeply unhappy about how long they actually live. ...

4 months ago
Kevin Gorman

Super director remuneration ...

4 months 1 week ago
Anthony Asher

No doubt true, but most of it is still because over 45’s have been upgrading their houses with 30 year mortgages. Money ...

4 months 1 week ago

Blue Owl Capital, a US asset manager with its eye on ‘marquee investors’ like super funds, has announced the appointment of a senior Future Fund executive as its newest m...

6 hours ago

Australia’s second-largest super fund has confirmed it is expanding its presence in the UK following significant investment in the region....

22 hours 18 minutes ago

While the Financial Advice Association Australia said it supports a performance testing regime “in principle”, it holds reservations about expanding this scope to retirem...

12 hours 37 minutes ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND